TOKYO, April 5, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TOA EIYO Ltd. (President: Atsuo Takahashi, Ph.D., “TOA EIYO”) today announced that the both companies have agreed to terminate the distribution agreement on March 31, 2022. In accordance with this agreement, after April 1, 2022, TOA EIYO will independently sell and provide information on all 18 products such as Bisono® tape, a transdermal patch of β1 blocker, for treatment of hypertension and atrial fibrillation and Frandol® tablets and tape for treatment of ischemic heart disease, which TOA EIYO obtained Marketing Authorization in Japan, that are currently sold on consignment by Astellas.
Astellas and TOA EIYO has collaborated for sales and marketing for a long time. Astellas currently sells most of the products which TOA EIYO obtained Marketing Authorization in Japan, and TOA EIYO provides their product information to medical institutions. The both companies have discussed and agreed to terminate the distribution agreement on March 31, 2022.
Astellas is continuously working on optimizing the allocation of management resouces in order to maximize the value of each product, and the termination of the distribution agreement is part of this effort. As a specialty pharmaceutical company in the field of cardiovascular medicine, TOA EIYO has decided that it is necessary to establish its own sales structure of products in order to meet the diverse needs of cardiovasculartreatment.
Astellas and TOA EIYO will work closely during the sales transfer process to ensure stable supply of the relevant products and a smooth continuation of activities, including the provision/collection of product information and the promotion of their proper use.
Click below for a copy of the full press release
